CHMP to review Tysabri as PML cases hit 23
This article was originally published in Scrip
The CHMP is to review the "benefits and risks" of Elan/Biogen Idec's Tysabri (natalizumab) for the treatment of multiple sclerosis, based on an increasing rate of progressive multifocal leucoencephalopathy (PML). The CHMP reported that 23 cases of PML occurred worldwide since launch, higher than the 13 previously disclosed. Biogen Idec shares dropped by 7% on Nasdaq on October 23rd on the news, whereas Elan shares fell by around 17.5% on the NYSE.